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Introduction. To assess the performance of five previously described clinicopathological definitions of low-risk prostate cancer (PC).
Materials and Methods. Men who underwent radical prostatectomy (RP) for clinical stage ≤T2, PSA <10 ng/mL, Gleason score <8
PC, diagnosed by transperineal template-guided saturation biopsy were included. The performance of five previously described
criteria (i.e., criteria 1–5, criterion 1 stringent (Gleason score 6 + ≤5mm total max core length PC + ≤3mm max per core length
PC) up to criterion 5 less stringent (Gleason score 6-7 with ≤5% Gleason grade 4) was analysed to assess ability of each to predict
insignificant disease in RP specimens (defined as Gleason score ≤6 and total tumour volume <2.5mL, or Gleason score 7 with
≤5% grade 4 and total tumour volume <0.7mL). Results. 994 men who underwent RP were included. Criterion 4 (Gleason score
6) performed best with area under the curve of receiver operating characteristics 0.792. At decision curve analysis, criterion 4 was
deemed clinically the best performing transperineal saturation biopsy-based definition for low-risk PC.Conclusions. Gleason score
6 disease demonstrated a superior trade-off between sensitivity and specificity for clarifying low-risk PC that can guide treatment
and be used as reference test in diagnostic studies.
1. Introduction
Early detection of prostate cancer (PC) has reduced PC
mortality, but at the cost of a substantial increase in overde-
tection of insignificant disease [1, 2]. As a result, there are
concerns about overdiagnosis and overtreatment of PC, and
this has led to alternative diagnostic strategies and more
conservative approaches, especially in the treatment of low-
risk disease. Furthermore, as PC ismost frequently a relatively
slow-growing tumour, complications of unnecessary curative
management in low-risk PC may be obviated by active
surveillance (AS) [3]. Over the last decade, this has resulted
in a growing acceptance of active surveillance for men
diagnosed with low-risk PC [3].
Additionally, the emergence of multiparametric MRI
(mpMRI) now allows imaging-based identification of PC,
which improves diagnostic accuracy for higher-risk tumours,
and might simultaneously reduce the diagnosis of low-risk
PCs (overdiagnosis) [4, 5]. Considering the unreliability of
PSA testing and 12-core template biopsy in PC diagnosis
and risk stratification, the ability to visualise the tumour
and then assess tumour grade and volume is of significant
clinical benefit. However, to analyse the accuracy of mpMRI,
a prospectively validated definition of clinically low-risk PC
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on saturation template mapping biopsy is required. mpMRI
detects both high-grade and larger tumours accurately, which
means it may perform particularly well for detection of
clinically significant disease [4]. For diagnostic evaluation of
mpMRI the ideal reference test would be definitive pathology
of whole-mount sections of radical prostatectomy specimens.
However, since such a reference test is not applicable in
clinical practice, a reference test based on transperineal
saturation biopsies would be useful [4].
There are multiple perspectives on low-risk PC (e.g.,
clinical, epidemiological, and pathological), and several def-
initions and terminologies are available [6]. The definition
of “insignificant” or so-called “low-risk” PC, as well as
the selection of men for AS, has been traditionally guided
by clinicopathological features found to be predictive of
indolent PC based on whole gland histopathology of radical
prostatectomy (RP) specimens and defined as an organ-
confined, well differentiated tumour (Gleason score ≤3 +
3 or ≤3 + 4) with a total tumour volume not exceeding
0.5–2.5mL [7, 8]. Obviously, the use of the definition of
pathologically insignificant PC requires an examination of
the entire prostate. The translation, in clinical terms, of this
histopathological definition of insignificant PC has proven
to be challenging, owing to inherent inaccuracies of biopsy
diagnoses. As a result, these definitions have been criticized
for high rates of Gleason upgrading and unfavourable disease
at RP [9–11]. Furthermore, it is unclear how to apply eligibility
criteria based on 6–12 cores compared to men undergoing
saturation biopsy [12–15].
The objective of this study was to assess the utility of
five transperineal saturation biopsy-based clinicopathologi-
cal risk criteria to predict insignificant PC in RP specimens.
Thus the most accurate definition of low-risk PC based on
transperineal saturation biopsiesmay be used as the endpoint
(reference test) for future diagnostic imaging and biomarker
studies. It may also be used to select candidate for AS after a
PC diagnosis based on transperineal saturation biopsies.
2. Materials and Methods
2.1. Characterization of the Study Population. Since 2000,
data from patients who underwent radical prostatectomy
at our centre was collected prospectively in an institutional
database. Institutional review board approval was granted
and informed consent was obtained in all patients. For
the present study, all men aged over 40 years, with PSA
≤10 ng/mL, diagnosed with a clinical T1c or T2, with Gleason
<8 PC by transperineal template-guided mapping biopsy,
betweenMay 2001 andMarch 2015, and treated with a radical
prostatectomy within 6 months of diagnosis, were included.
All patients were reviewed and treated by two urologists at St
Vincent’s Clinic, Sydney, Australia.
2.2. Study Protocol. All men underwent biopsy for abnormal
PSA or DRE. Transperineal template-guidedmapping biopsy
was performed with a median of 30 cores using 5mm sam-
pling of the peripheral zone and limited sampling of the tran-
sition zone with relative periurethral zone sparing adjusted
Table 1: Five transperineal saturation biopsy-based criteria for low-
risk prostate cancer.
Criteria Definition
Criterion 1 Gleason score 6 + ≤5mm total max core length PC +
≤3mmmax per core length PC
Criterion 2 Gleason score 6 + <20% of cores positive + <5mmmax core length PC
Criterion 3 Gleason score 6-7 with ≤5% Gleason grade 4 + <20%of cores positive + <7mmmax core length PC
Criterion 4 Gleason score 6
Criterion 5 Gleason score 6-7 with ≤ 5% Gleason grade 4
for volume from 18 template locations. Histopathology from
biopsies was processed and reported according to ISUP
(International Society of Urological Pathology) protocols by
one uropathologist. For all biopsies, the length of cancer was
in millimetres (mm) and a primary and secondary Gleason
grade were assigned to each cancer-containing core.
Subsequently all men underwent nerve sparing radi-
cal prostatectomy (open or robotic). Histopathology from
radical prostatectomy specimens was processed following
previously described protocols [16]. All specimens were fixed,
inked, and cut at 3mm intervals perpendicular to the rectal
surface. The apical slice was cut parasagittally at 3mm inter-
vals. Pathological tumour stage, Gleason score, and surgical
margin status were assessed. Tumour areas were marked for
each slide and measured using 3D volume estimation.
2.3. Criteria Tested. A literature search was performed to
identify published definitions for “insignificant”, “indolent”,
or “low-risk” PC based on transperineal saturation biopsies.
In total five clinicopathological definitions of low-risk PC
were included and analysed, Table 1 [5, 8, 17]. In the present
study, significant PC on radical prostatectomy specimen was
defined, using the updated criteria, as PC with Gleason score
3 + 3 = 6 and a total tumour volume of ≥2.5mL and as any PC
of Gleason score 7–10 with greater than 5% Gleason grade 4
or higher and a total tumour volume of ≥0.7mL [7].
2.4. Development PredictionModel. For descriptive statistical
analysis, firstly the rates of significant PC with specific
pathologically unfavourable PC characteristics, defined as the
presence of either extracapsular extension, seminal vesicle
invasion, lymph node invasion, or Gleason score 7–10 that
fulfilled the proposed five criteria for low-risk disease, were
assessed. Secondly, binary logistic regression was performed
to explore the relationship between serumPSA, clinical stage,
prostate volume, percentage of positive biopsy cores, and
insignificant PC (yes/no) among all patients and individually
for the patients that fulfilled the five criteria for low-risk dis-
ease. Sensitivity, specificity, negative predictive value (NPV),
and positive predictive value (PPV) were assessed for all five
criteria to predict insignificant PC in radical prostatectomy
specimens.
The discrimination of the various criteria was tested using
area under the curve of receiver operating characteristic
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Table 2: Patients characteristics.
Variable All Criterion 1 Criterion 2 Criterion 3 Criterion 4 Criterion 5
Number of patients 994 52 78 127 219 319
Median (IQR)
Age 62 60 (57–63) 60 (56–64) 60 (55–64) 59 (55–63) 60 (55–64)
PSA ng/mL 5.5 5.5 (4.0–7.2) 5.5 (4.2–6.8) 5.5 (4.1–7.0) 5.1 (3.8–6.3) 5.1 (3.8–6.3)
Prostate volume 49.0 53.0 (45–69) 53.0 (44–70) 52.0 (44–62) 49.0 (41–57) 48.0 (40–56)
Number of cores 27 28 28 28 28 28
% positive cores 25.0 9.5 11.1 12.5 18.8 21.4
Clinical stage,𝑁 (%)
T1c 537 (54.0) 43 (82.7) 62 (79.5) 93 (73.2) 151 (68.9) 208 (65.2)
T2a 312 (31.4) 5 (9.6) 11 (14.1) 22 (17.3) 47 (21.5) 73 (22.9)
T2b 72 (7.3) 1 (1.9) 2 (3.8) 3 (2.4) 11 (5.0) 15 (4.7)
T2c 73 (7.3) 3 (5.8) 3 (2.6) 9 (7.1) 10 (4.6) 23 (7.2)
Biopsy Gleason score,𝑁 (%)
3 + 3 221 (22.2) 52(100) 78 (100) 99 (78.0) 219 (100) 218 (68.3)
3 + 4 581 (58.5) 28 (22.0) 101 (31.7)
4 + 3 192 (19.3)
Table 3: Unfavourable pathological characteristics per biopsy criteria.
Variable Criterion 1 Criterion 2 Criterion 3 Criterion 4 Criterion 5
Number of patients 52 78 127 219 319
Gleason score
4 + 3 (%) 1 (1.9) 2 (2.6) 1 (0.8) 3 (1.4) 5 (1.6)
≥8 (%) 0 (0.0) 0 (0.0) 2 (1.6) 1 (0.3) 3 (0.9)
ECE (%) 4 (7.7) 6 (7.7) 11 (8.7) 28 (12.8) 55 (17.2)
SVI (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
LNI (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Any unfavourable pathological characteristics 5 (9.6) 7 (8.9) 13 (10.2) 29 (13.2) 57 (17.9)
(AUC-ROC) analysis. Discrimination describes the model’s
ability to differentiate between those with and those without
the outcome of interest, in this case the presence of insignif-
icant PC. 𝑃 values were calculated to indicate whether the
AUC was significantly different to the null hypothesis (AUC
of 0.5).
Decision curve analysis (DCA) was used to plot the net
clinical benefit, measured by weighing the benefits (true pos-
itive results) against the harms (false positives), at different
probability thresholds, thus yielding the decision curve [18].
Decision curve analysis generated a graph of the net benefit
as a function of a threshold probability (𝑝
𝑡
) at which an
individual considers the potential benefit andharmof surgery
to be equivalent. The threshold probability of insignificant
cancer is an assumption where the patient would opt for AS.
The decision curve is then compared with the two extremes
of assuming all or no patients being treated with RP. The net
benefit was measured as the rate at which incorporating the
decision guide of interest (identifying low-risk PC) would
lead to a beneficial decision to diagnose and treat PC without
causing any additional harmful decisions to overtreat PC.
For all analyses, two-sided 𝑃 values <0.05 were consid-
ered to be statistically significant. Statistical analyses were
performed using SPSS version 21 and the R statistics package.
3. Results
Patient characteristics are presented in Table 2. Between
May 2001 and March 2015, in total 3521 men underwent
RP. 994 (28.2%) men fulfilled the inclusion criteria (PSA ≤
10 ng/mL, diagnosed with clinical T1c or T2, Gleason <8 PC
based on transperineal template-guidedmapping biopsy) and
were included for analysis. Of these men, 48 (4.8%) had a
previous negative prostate biopsy. In 339 (34.1%) men a bilat-
eral extended pelvic lymph node dissection was performed
simultaneously to the RP. Of the 994 men who underwent
RP, 143 (14.4%) fulfilled the criteria for insignificant PC at RP.
Based on biopsy results, 52 (5.2%) men fulfilled criterion 1,
78 (7.8%) men fulfilled criterion 2, 188 (18.9%) men fulfilled
criterion 3, 219 (22.0%) fulfilled men criterion 4, and 319
(32.1%) fulfilled criterion 5.
Table 3 shows the percentages of unfavourable patholog-
ical characteristics among the patients that fulfilled the five
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Table 4:The ability of the five criteria to predict insignificant PC in
RP specimen.
Specificity Sensitivity PPV NPV
Criterion 1 98 23 63 88
Criterion 2 97 34 63 90
Criterion 3 91 52 46 93
Criterion 4 86 72 47 95
Criterion 5 76 82 37 96
Table 5: Outcomes of area under the receiver operating character-
istic analysis of the five biopsy criteria.
AUC 95% CI P value
Criterion 1 0.604 0.549–0.660 <0.01
Criterion 2 0.654 0.599–0.712 <0.01
Criterion 3 0.641 0.641–0.749 <0.01
Criterion 4 0.792 0.747–0.837 <0.01
Criterion 5 0.790 0.750–0.831 <0.01
low-risk criteria.The number ofmenwith a Gleason ≥4 + 3 at
RP specimen and/or extracapsular disease was highest upon
applying the least stringent criteria (criterion 5, 17.9%).
3.1. Risk Stratification. Multivariable logistic regression of
preoperative clinicopathological parameters predicting insig-
nificant PC at RP was performed. Significant variables pre-
dicting insignificant disease among all men included were
lower PSA (OR 0.77, 95% CI 0.70–0.86), younger age (OR
0.92, 95% CI 0.92–0.98), larger prostate volume (OR 1.02,
95% CI 1.01–1.04), smaller percentage positive biopsies (OR
0.96, 95% CI 0.95–0.98), and a normal rectal examination
(OR 0.56, 95% CI 0.37–0.85). The −2 log likelihood of the
model was 689.35, specificity was 98.8%, sensitivity was 8.4%,
and overall success ratewas 85.8%. Regression coefficients (𝐵)
were−0.579 for normal rectal examination,−0.255 per ng/mL
serum PSA, −0.080 per year of age, −0.039 per % positive
biopsies, and 0.024 per cm3 prostate volume.
3.2. Performance of the 5 Transperineal Saturation Biopsy-
Based Criteria. The ability of the five criteria to predict
insignificant PC in RP specimen was examined, showing
a sensitivity that ranged between 23% (criterion 1) and
82% (criterion 5) and a specificity that varied between 76%
(criterion 5) and 98% (criterion 1). The sensitivity, specificity,
PPV, NPV, and LR for all five criteria are presented in Table 4.
Receiver operator characteristics to assess the performance
of the five biopsy-based criteria, to predict insignificant PC
in RP, are shown in Table 5. The AUC for each model
ranged between 0.604 (criterion 1), 0.654 (criterion 2), 0.741
(criterion 3), 0.790 (criterion 5), and 0.792 (criterion 4),
suggesting moderate positive discrimination at best.
A DCA was performed to assess the clinical utility of
using each of the five criteria for the definition of low-risk PC
to guide the decision of who should not be treated (in order
to decrease overtreatment) and/or be selected for AS. Two
additional criteria (treatment with RP to all and treatment
to none) were added for comparison. The DCA showed
that, for threshold probabilities of 0% to 15%, representing a
preference to maximize reduction in overtreatment, the net
benefit is greatest using criterion 5. In this range of threshold
probabilities, patients appear to be more concerned about
overtreatment than about missing significant PC. For the
midrange, as well as clinically most relevant probabilities of
30% to 50%, criterion 4 was superior to the other criteria.
For the higher thresholds (50–75%), at which patients may
be more concerned about missing a significant cancer than
about unnecessary overtreatment, the more rigorous criteria
1 and 2 should be used. Using a threshold of >75% is best to
diagnose and/or treat all patients.
4. Discussion
“Overdiagnosis” and “overtreatment” are defined as the
diagnosis and/or treatment of PC that would never cause
symptoms or death during the patient’s lifetime and may
therefore be considered unnecessary [19]. Obviously, both
definitions are influenced by disease-related factors and by
the natural life expectancy of a patient. “Indolent” PC is
defined as a cancer that never becomes locally invasive or
metastatic leading to symptoms or death, irrespective of the
patient’s comorbidities or expected lifespan [6, 8]. This is in
contrast to the term “insignificant,” which is epidemiologi-
cally defined and based on lifetime risk estimations of the
occurrence of symptomatic or clinical PC in a population.
Consequently, a tumour classified as nonindolent in a patient
who dies of an unrelated cause and has not experienced
morbidity from PC will also be classified as overdiagnosed.
Overdiagnosis has been estimated between 22 and 67% using
different screening regimens [2]. In this context, defining
low-risk or insignificant PC in a considerable percentage of
PCs is an important diagnostic step. In our study cohort,
using five different biopsy-based criteria, 6% to 32% of men
were classified as having low-risk PC.
In outlining a definition for low-risk PC to reduce over-
diagnosis and minimize morbidity associated with overtreat-
ment of PC, the ability to “accurately” select men is
paramount. In the present study, we analysed five criteria to
predictmenwith insignificant PC atRP specimen, a surrogate
for low-risk PC and/or suitability for AS. Not surprisingly,
the specificity was better among the more stringent criteria
for low-risk PC (criteria 1 and 2). In contrast the AUCs were
found to be significantly higher among the less stringent
criteria (criteria 4 and 5). For our specific research ques-
tion, specificity might take precedence over sensitivity and
therefore a DCA was performed to determine clinical utility
(Figure 1). Based on clinical acceptance, the criteria with the
highest sensitivity by a specificity of 90% would be assumed
as the optimal definition for clinical use [2, 3]. As a result,
criteria 3 and 4 may be used for further patient selection and
validation purposes.
Furthermore, it should be noted that the benefits of early
detection and active treatment are limited, and ultimately
what is required is improved selection of patients with signif-
icant PC who will benefit from immediate active treatment
[1, 2]. In this study, it was observed that the application
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Figure 1: Decision curve analysis, demonstrating the net benefit,
as measured by rate of nontreating men for low-risk prostate
cancer, using the five decision-making strategies as listed in the
legend. Threshold probability is the threshold probability of low-
risk PC at which an individual considers the benefit of treatment
for PC equivalent to the harm of overtreatment for low-risk disease,
and thus it reflects how the individual weights the benefits and
harms associated with this decision. The highest curve at any given
threshold probability is the optimal decision-making strategy to
maximize net benefit.
of more liberal criteria would enable 3.6-fold more men to
participate in AS program, resulting in a 10% increased risk of
underestimating a significant PC (criterion 3 versus criterion
1). In other words, among the present study population,
we would decrease the “overdiagnosis” by 13.7% if we only
diagnosed insignificant PC using criterion 3 (18.9%) versus
criterion 1 (5.2%). In our opinion, these trade-offs could be
beneficial, in terms of both quality of life and financial costs
related to the early detection of PC [20]. Finally, given the
slow evolution of PC, a deferment in definitive treatment
would not be likely to substantially alter disease course or
limit the patient’s chance of complete cure [21].
Finally, the results also showed that, even with the
most stringent selection criteria, it is impossible to perfectly
differentiate between clinically insignificant and possible life-
threatening PC, even after a diagnosis based on transperineal
saturation biopsies. Suardi et al. reported rates of 24 to 27.8%
of unfavourable PC characteristics in a cohort based on 2 of
the most “stringent” criteria looking at 12-core TRUS guided
biopsies [9]. Other series reported rates of 8.4–30.5% of
unfavourable outcomes in a 12-core TRUS population fulfill-
ing the Epstein criteria [11, 22, 23]. Ultimately, to accurately
identify insignificant cancer we will need to look beyond
histopathology in isolation, integrating biopsy data with
the high-resolution 3D mapping and functional information
derived from mpMRI and possibly that from biomarkers
(PCA3, pro-2 PSA, and TMPRSS2:erg), mitochondrial RNA
mapping (e.g., PC Mitomics Test), epigenetic DNA mapping
(e.g., MDx Link), and other emerging predictors of the
biologic behaviour of PC in an individualised way [24–28].
Results from the present study may be used for further
development of mpMRI protocols. For evaluation of mpMRI
performance, ideally inclusion of definitive pathology is
required from whole-mount sections of RP specimens as the
reference standard [4]. However, since such study designs
are not applicable in clinical practice due to the selection
biases created by the absence of RP specimens in patients
who have no cancer on biopsy low-risk cancer managed
with AS or high-risk cancer managed with radiotherapy,
an alternative approach is to use transperineal saturation
template prostate mapping biopsy instead [4]. Transper-
ineal saturation template mapping biopsy outperforms TRUS
guided prostate biopsies, showing an average upgrading in
33% of patients and a change from unilateral to bilateral
disease in more than 50% of patients [29]. The present study
aids the interpretation of the outcomes of this alternative
and demonstrates that saturation biopsy is not a perfect
reference standard. Biopsy criterion 3 and criterion 4 showed
a specificity and NPV of 86–88% and 93–95%, respectively,
for accurately predicting insignificant PC in RP, and therefore
may represent clinically relevant definitions for selection of
active surveillance patients.
The present study is subject to limitations. Firstly, this
was a retrospective analysis of prospectively collected data
from only two surgeons in a single centre. Secondly, there
is a major selection bias towards higher-risk patients, given
that the cohort consists entirely of patients who underwent
RP, a decision which may have been driven by unmeasured
clinical factors such as a rapidly rising PSA or significant
lesions on mpMRI. This could negatively bias the accuracy
estimates for each definition. It is a highly selected study
population with no control arm. Furthermore, given the long
period over which this study data was collected, changes in
Gleason reporting for PC may also represent a confounder
regarding biopsy and RP specimen pathology. Also, diag-
nostic performance in terms of sensitivity and specificity
are subject to inclusion criteria. We included only low-risk
men diagnosed with clinical stage ≤T2, PSA <10 ng/mL, and
Gleason score <8 PC in order to estimate the performances of
the diagnostic criteria in low-risk patients. Diagnostic perfor-
mancemay differ in higher-risk patients, who are less likely to
harbour insignificant disease and are not usually candidates
for AS. Furthermore, transperineal saturation biopsies are
not generally accepted as a reference test [4], and it is still
unclear if transperineal saturation biopsiesmight detectmore
insignificant cancers compared to a standard biopsy. Finally,
prospective studies that use these biopsy definitions to select
patients for AS and then evaluate long-term oncological
outcomes will provide a higher level of evidence. However,
until such studies are published, retrospective studies such as
this can be used to guide patient counselling and treatment
decisions.
In conclusion, balancing overtreatment of insignificant
PC with undertreatment of significant PC is an ongoing
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challenge. This study analysed the performance character-
istics of various criteria at predicting insignificant PC on
transperineal template-guided saturation mapping biopsies
in a relatively low-risk PC population who underwent RP.
No single definition was superior; however, patients with
Gleason 6 disease demonstrated the best trade-off between
sensitivity and specificity for clarifying low-risk PC. Depend-
ing on patients and physicians preferences, these criteria can
be used for treatment decisions and patient counselling and
as a reference test in diagnostic studies.
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